- Home
- ZUMZ vs DMAC Comparison
ZUMZ vs DMAC Comparison
Compare ZUMZ & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZUMZ
- DMAC
- Stock Information
- Founded
- ZUMZ 1978
- DMAC 2000
- Country
- ZUMZ United States
- DMAC United States
- Employees
- ZUMZ N/A
- DMAC N/A
- Industry
- ZUMZ Clothing/Shoe/Accessory Stores
- DMAC Biotechnology: Pharmaceutical Preparations
- Sector
- ZUMZ Consumer Discretionary
- DMAC Health Care
- Exchange
- ZUMZ Nasdaq
- DMAC Nasdaq
- Market Cap
- ZUMZ 274.4M
- DMAC 267.7M
- IPO Year
- ZUMZ 2005
- DMAC N/A
- Fundamental
- Price
- ZUMZ $14.40
- DMAC $4.98
- Analyst Decision
- ZUMZ Hold
- DMAC Strong Buy
- Analyst Count
- ZUMZ 2
- DMAC 3
- Target Price
- ZUMZ $22.00
- DMAC $8.00
- AVG Volume (30 Days)
- ZUMZ 340.9K
- DMAC 74.9K
- Earning Date
- ZUMZ 03-13-2025
- DMAC 03-17-2025
- Dividend Yield
- ZUMZ N/A
- DMAC N/A
- EPS Growth
- ZUMZ N/A
- DMAC N/A
- EPS
- ZUMZ N/A
- DMAC N/A
- Revenue
- ZUMZ $889,202,000.00
- DMAC N/A
- Revenue This Year
- ZUMZ $3.43
- DMAC N/A
- Revenue Next Year
- ZUMZ $1.97
- DMAC N/A
- P/E Ratio
- ZUMZ N/A
- DMAC N/A
- Revenue Growth
- ZUMZ 1.57
- DMAC N/A
- 52 Week Low
- ZUMZ $12.67
- DMAC $2.14
- 52 Week High
- ZUMZ $31.37
- DMAC $6.82
- Technical
- Relative Strength Index (RSI)
- ZUMZ 48.60
- DMAC 34.11
- Support Level
- ZUMZ $12.67
- DMAC $5.49
- Resistance Level
- ZUMZ $15.29
- DMAC $5.47
- Average True Range (ATR)
- ZUMZ 0.77
- DMAC 0.35
- MACD
- ZUMZ 0.24
- DMAC -0.11
- Stochastic Oscillator
- ZUMZ 66.03
- DMAC 6.32
About ZUMZ Zumiez Inc.
Zumiez Inc is a United-States-based specialty retailer engaged in the sale of apparel, footwear, accessories, and hard goods. The company provides merchandise with cultural elements coming from fashion, music, art from action sports, streetwear, and other lifestyles. The company operates under the brands Zumiez, Fast Times, and Blue Tomato, and through both physical stores and websites. The majority of the company's stores are located in the U.S., with the rest in Canada, Australia, and Europe. The U.S. market contributes to the majority of the company's revenue.
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is principally engaged in the business activity of developing treatments for unmet clinical needs or where no therapies are available with a primary focus on chronic kidney disease and acute ischemicstroke. Its pipeline product DM199 is a recombinant form of human tissue kallikrein-1.